Fair-skinned people - who traditionally burn the most in the sun - benefited most from an anti-sunburn drug which has finished Phase II human trials, the Professor of Dermatology at Sydney University said today.
Professor Ross Barnetson - a world authority in the field of photobiology, ultraviolet skin damage and the immunology of skin tumours - ran the Phase II human trials at Sydney University, alongside a concurrent trial at Royal Adelaide Hospital. Eighty volunteers took part in the trial.
Results of the trial into the drug Melanotan - which stimulates the production of melanin in the skin - showed that:
"The aim of the trial was to determine how Melanotan could reduce the degree and toxicity of sunburn in 80 healthy volunteers exposed to ultraviolet light both before and after a regime of the drug," said Professor Barnetson. "The fair-skinned people who took Melanotan had half the skin damage after the study compared to before the study. The results showed that fair-skinned people who have developed a tan are less likely to burn."
The drug was administered daily for ten days in each of three consecutive months. Twenty volunteers received placebos. The volunteers, of varying skin types, received controlled levels of UVA and UVB radiation onto a small area of skin resulting in a level of burning similar to spending 30-120 minutes in strong sun without sunscreen. A skin biopsy was taken from each to measure the level of resulting sunburn injury. The volunteers then received a regime of Melanotan, the same UV radiation exposure, and another skin biopsy.
A volunteer in the trial, Rachel Preece, a 25-year-old medical student, said that the drug gave her an even, all-over tan. She said she recognised the protective elements of the tan. "I am not a sun-lover and don’t go on the beach often. Being a medical student I see a lot of bad effects of sun-baking with skin cancers. I would take this drug if it was commercialised."
Professor Alan Cooper, Head of the Department of Dermatology at Sydney’s Royal North Shore Hospital, said: "I think its reasonable that we can consider Melanotan to be an internal sunscreen. Melanin is the body’s natural sunscreen and this is a way of increasing the amount of melanin we have."
Dr Wayne Millen, Managing Director of EpiTan - the biotechnology company developing Melanotan - said he was delighted with the results. "The results improve our chances of commercialising the world’s first prescription sunscreen. There is no other product available today to prevent sunburn apart from sunscreen. We expect Melanotan to be especially beneficial to those people with fair skin types who are most at risk of sunburn injury and therefore of developing skin cancers."
EpiTan recently announced that, following a successful meeting with the United States Food & Drug Administration, it would lodge an Investigational New Drug application in mid-2004. Clinical trials for a newly-developed long-acting implant has begun at Q-Pharm in Queensland. This trial is expected to conclude in May 2004.
For more information contact:
Professor Ross Barnetson, Sydney University, 02 9515-6861
Mr Iain Kirkwood, Chief Administrative Officer, EpiTan Limited, Tel: 03 9662-4688 or 0408 473 496
Mr Richard Allen, Monsoon Communications, Tel: 03 9620-3333 or 0403 493 049
Rebecca Piercey | Monsoon Communications
Cystic fibrosis alters the structure of mucus in airways
28.06.2017 | University of Iowa Health Care
Mice provide insight into genetics of autism spectrum disorders
28.06.2017 | University of California - Davis
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
28.06.2017 | Physics and Astronomy
28.06.2017 | Physics and Astronomy
28.06.2017 | Health and Medicine